Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review

Area of Science:

• Neuroimmunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic neurodegenerative condition with no cure, necessitating therapies to mitigate relapse and disability.
• Recent advancements include disease-modifying therapies (DMTs) and immune reconstitution therapies (IRTs) for MS management.

Purpose of the Study:

• To provide an overview of immune reconstitution therapy (IRT) in the context of multiple sclerosis (MS).
• To offer a clinician's perspective on the current MS treatment landscape, focusing on cladribine tablets.
• To present practical advice for managing patients treated with cladribine tablets, incorporating recent evidence.

Main Methods:

• Review of current literature on IRT and cladribine tablets for MS.
• Analysis of the mechanism of action of IRT, including the 3Rs: reduction, repopulation, and reconstitution of lymphocytes.
• Discussion of cladribine tablets as an oral IRT targeting lymphocytes while sparing innate immune cells.

Main Results:

• Cladribine tablets represent a selective, oral IRT for MS with high efficacy.
• Treatment involves short dosing periods (two courses in Years 1 and 2), potentially improving adherence and reducing monitoring burden.
• The review addresses practical management aspects, including COVID-19 risks and vaccination recommendations for MS patients.

Conclusions:

• Cladribine tablets offer a valuable IRT option for MS, characterized by selective lymphocyte targeting and a convenient dosing schedule.
• Effective management of MS with cladribine tablets requires consideration of recent evidence, including infection risks and vaccination strategies.
• The clinician's perspective highlights the practical benefits and considerations for integrating cladribine tablets into MS treatment plans.